

DESCRIPTION

Source	Human embryonic kidney cell, HEK293-derived cynomolgus monkey IL-6 protein Ala28-Met212 Accession # NP_001274245.1
N-terminal Sequence Analysis	Ala28
Predicted Molecular Mass	21 kDa

SPECIFICATIONS

SDS-PAGE	20-30 kDa, under reducing conditions
Activity	Measured in a cell proliferation assay using T1165.85.2.1 mouse plasmacytoma cells. Nordan, R.P. <i>et al.</i> (1987) J. Immunol. 139 :813. The ED ₅₀ for this effect is 0.25-1.25 ng/mL.
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 500 µg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	<p>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</p> <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA

<p>Bioactivity</p> <p>Recombinant Cynomolgus Monkey IL-6 (Catalog # 10510-IL) stimulates cell proliferation of the T1165.85.2.1 mouse plasmacytoma cell line. The ED₅₀ for this effect is 0.25-1.25 ng/mL.</p>	<p>SDS-PAGE</p> <p>2 µg/lane of Recombinant Cynomolgus Monkey IL-6 Protein (Catalog # 10510-IL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 20-30 kDa.</p>
--	---

BACKGROUND

Interleukin-6 (IL-6) is a pleiotropic, variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression (1-5). IL-6 exhibits a classic four helix bundle protein structure with its alpha-helices found in an anti-parallel arrangement (6). Mature cynomolgus IL-6 shares 96% amino acid sequence identity with human IL-6. Alternative splicing generates several isoforms with internal deletions, some of which exhibit antagonistic properties (7-10). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R alpha) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R alpha, triggering IL-6 R alpha association with gp130 and gp130 dimerization (11). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (12). Soluble forms of IL-6 R alpha are generated by both alternative splicing and proteolytic cleavage (5). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R alpha elicit responses from gp130-expressing cells that lack cell surface IL-6 R alpha (5). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R alpha is predominantly restricted to hepatocytes, monocytes, and resting lymphocytes (2, 5). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R alpha but not from other cytokines that use gp130 as a co-receptor (5, 13). IL-6, along with TNF-alpha and IL-1, drives the acute inflammatory response and the transition from acute inflammation to either acquired immunity or chronic inflammatory disease (1-5). When dysregulated, it contributes to chronic inflammation in obesity, insulin resistance, inflammatory bowel disease, arthritis, sepsis, and atherosclerosis (1, 2, 5). IL-6 can also function as an anti-inflammatory molecule, as in skeletal muscle where it is secreted in response to exercise (2). In addition, it enhances hematopoietic stem cell proliferation and the differentiation of Th17 cells, memory B cells, and plasma cells (1, 14).

References:

1. Mansell, A. and B.J. Jenkins (2013) *Cytokine Growth Factor Rev.* **24**:249.
2. Schuett, H. *et al.* (2009) *Thromb. Haemost.* **102**:215.
3. Erta, M. *et al.* (2012) *Int. J. Biol. Sci.* **8**:1254.
4. Garbers, C. *et al.* (2012) *Cytokine Growth Factor Rev.* **23**:85.
5. Mihara, M. *et al.* (2012) *Clin. Sci. (Lond.)* **122**:143.
6. Somers, W. *et al.* (1997) *EMBO J* **16**:989.
7. Kestler, D.P. *et al.* (1995) *Blood* **86**:4559.
8. Kestler, D.P. *et al.* (1999) *Am. J. Hematol.* **61**:169.
9. Bihl, M.P. *et al.* (2002) *Am. J. Respir. Cell Mol. Biol.* **27**:48.
10. Alberti, L. *et al.* (2005) *Cancer Res.* **65**:2.
11. Murakami, M. *et al.* (1993) *Science* **260**:1808.
12. Muller-Newen, G. (2003) *Sci. STKE* **2003**:PE40.
13. Mitsuyama, K. *et al.* (2006) *Clin. Exp. Immunol.* **143**:125.
14. Cerutti, A. *et al.* (1998) *J. Immunol.* **160**:2145.